Is Prime Medicine, Inc. Common Stock (PRME) overvalued at rev $3.0M?

Prime Medicine, Inc. Common Stock (PRME) rev $3.0M.

Is this a short call on PRME?

No. A rich cached multiple is not a short thesis.

Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.

This page asks whether Prime Medicine, Inc. Common Stock (PRME) looks expensive on cached numbers — not a short thesis.

Latest reported PRME revenue for 2024-12-31 was $3.0M. Net income was -$195.9M. PRME currently screens at market cap $570.8M.

PRME currently screens at market cap $570.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.

If the next PRME 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.

Not investment advice. Use the PRME stock page for the full model, not this heading.

Not investment advice.